STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Diamyd Medical (NASDAQ:DMYDY) (STO:DIAMB) announces today that Diamyd® vaccination, still after five years, significantly lowers the risk that LADA patients (Latent Autoimmune Diabetes in Adult) need insulin treatment. No treatment related serious adverse events were seen in the study, further strengthening the safety profile of Diamyd®.
